Gelonghui, May 9 | Fuxiang Pharmaceutical (300497.SZ) said on the investor interactive platform that synthetic biology is an emerging discipline that uses renewable biomass as raw materials and organisms as production media to transform or create artificial life systems. Synthetic biology has characteristics such as being clean, efficient, and renewable. It has the potential to completely disrupt the current pattern at both the level of technology and industrial innovation, and is an important development direction for the company. Currently, the company has built its own multi-functional synthetic bio-biological fermentation production line, and has accumulated deep experience in biological fermentation technology, which is mainly used in the fields of medicine and food. The company applied synthetic biology technology to various enzyme preparations, hydroxyproline, microbial proteins and other products. Among them, the company's microbial fermented protein has achieved a pilot production scale of kilotons. In order to meet market demand, the company plans to invest in the construction of a comprehensive utilization project with an annual output of 200,000 tons of microbial protein and its resources (20,000 tons in the first phase). After the project is completed and put into operation, it can produce 20,000 tons of microbial protein and 50,000 tons of amino acid water-soluble fertilizer per year. The project is progressing in an orderly manner. Currently, this business has not had a significant impact on the company's performance.